Gynecologic Oncology Biannual Meeting
Spring 2021 Meeting
Welcome
Zoom Meeting-Changing Your Display Name

1. After launching the Zoom meeting, click on the "Participants" icon at the bottom of the window.

2. In the "Participants" list on the right side of the Zoom window, hover over your name and click on the "Rename" button.

3. Type in the display name you’d like to appear in the meeting and click on "OK".

First name, Last name, Affiliation
Zoom Meeting Reference Sheet

- Camera off
- Camera on
- Mute
- Stop Video
- Chat
- Share Screen
- Record
- Reactions
- Access chat window to type questions & comments
- Speaker View
- Gallery View
- Thumbs up
- Clapping Hands
- Party Popper (Celebration)
Select 1 core value that you admire the **most** about MOQC.
Type your response in chat box.
Agenda
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Facilitator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Welcome &amp; Roll Call</td>
<td>Vanessa Aron, BA</td>
</tr>
<tr>
<td>9:05 am</td>
<td>Patient &amp; Caregiver Oncology Quality Counsel (POQC) Update</td>
<td>Amanda Itliong, MA</td>
</tr>
<tr>
<td>9:20 am</td>
<td>Data and VBR Updates/Measures and Trends MSQC Partnership Database Update</td>
<td>Shitanshu Uppal, MD</td>
</tr>
<tr>
<td>10:05 am</td>
<td>Open Discussion</td>
<td></td>
</tr>
<tr>
<td>10:40 am</td>
<td>Improving the Family History in People with Cancer MiGHT Project Resources for you</td>
<td>Shayna Weiner, MPH</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Measures Discussion</td>
<td>Shitanshu Uppal, MD</td>
</tr>
<tr>
<td></td>
<td>Close &amp; Wrap Up</td>
<td>Vanessa Aron, BA</td>
</tr>
<tr>
<td></td>
<td>• MOQC Biannual Meeting (Virtual), Friday, June 18th, 2021</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fall Gyn Onc Biannual Meeting (TBD), Saturday, November</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 2021 Meeting schedule - <a href="http://www.moqc.org/events/">ww.moqc.org/events/</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CME/CE/CEU Credits</td>
<td></td>
</tr>
</tbody>
</table>
POQC Update

Financial Toxicity

Caregiver Resources

Anti-Racism
Goals

Patient/Caregiver Education  
Physician Education  
Access to Resources

Financial Toxicity

- Resources
- Website
- Presenters

Caregiver Resources

- Resources
- Website
- Presenters

Anti-Racism

- Building Team
How You Can Help

Financial Toxicity
• What financial resources do you have for patients now?
• Do you have a content expert in finances at your practice?
• Topics we’re missing?
• Note: ACA Enrollment Period ends May 15th

Caregiver Resources
• Do you provide resources for advanced care directives to patients and caregivers now?
• Do you provide resources for/about caregivers to your patients and their loved ones?
• Topics we’re missing?

Anti-Racism
• Nominate yourself or a colleague to join the team!
• Amanda Itliong: akcrowell@gmail.com
Questions

To mute your microphone

To unmute your microphone

*6 to mute/unmute
# Round 2 2020 Important Dates

Charts abstracted July 7 – December 4, 2020

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Patients in Initial Therapy/Treatment (all cross cutting &amp; disease measures)</th>
<th>Patients who have Died (End of Life)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only gyn onc &amp; SMT modules Primary, secondary or interval cytoreduction to remove the ovary and/or fallopian tube, and/or adnexa (see next slide for additional info)</td>
<td>EOL Module ONLY for any cancer type</td>
<td></td>
</tr>
</tbody>
</table>
| Dx dates | 06/01/2019 – 09/30/2020  
June 1, 2019 – September 30, 2020 | Dx with invasive cancer on or before September 30, 2020 |
| First office visit | 06/01/2019 – 11/30/2020  
June 1, 2019 – November 30, 2020  
Not required to be within office visit window (below) – occur within dx window and end of visit window date | *List first visit date patient was seen in practice for documented diagnosis (see previous slide for additional info) |
| Two visits with practitioner | 04/01/2020 – 11/30/2020  
April 1, 2020 – November 30, 2020 | 2 office visits 9 months preceding death with date of death between 06/01/2019 – 11/30/2020 |

### Notes for Graph Interpretation:
- 0% and no bar graph = “0” in number / “x” number in denominator
- No percentage (%) and no bar graph = no denominator for calculation
Pain addressed appropriately by second office visit and during most recent office visits
N = 134

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Signed patient consent for chemotherapy
N = 101

QOPI Measure CORE14 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Tobacco cessation counseling administered or patient referred in past year
N = 15

QOPI Measure CORE22bb - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Infertility risks discussed prior to chemotherapy with patients of reproductive age
N = 5

QOPI Measure SMT33 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
End of Life Measures

Shitanshu Uppal, MD
Pain addressed appropriately
N = 16

QOPI Measure EOL38 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Dyspnea addressed appropriately
N = 16

QOPI Measure EOL41 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Hospice enrollment within 3 days of death (Lower score better)
N = 7

Q1 Median

QOPI Measure EOL44 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Hospice enrollment, or documented discussion
N = 16

QOPI Measure EOL47a - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Palliative care referral/services, or documented discussion

N = 16

QOLI Measure EOL47b - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Chemotherapy administered within the last two weeks of life
N = 16

QOPI Measure EOL48 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Gynecologic Oncology Measures
Shitanshu Uppal, MD
Days between Cytoreduction and 1st Day of Chemotherapy
N = 76

R1 + R2 2019:
Mean = 31.0
Median = 29

R1 2020:
Mean = 29.4
Median = 28

Quality Metric
28 days

Each bar = 1 Patient
Patients with ovarian cancer referred to genetic testing/counselling
N = 77

QOPI Measure GynOnc #2 - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
Operative report with documentation of residual disease
N = 85

QOPI Measure GYNONC90g - Practice and Comparative Groups
R2 2020

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.
MOQC Value Based Reimbursement (VBR)

**ELIGIBILITY**

Collaborative meets target for 2 designated VBR QOPI measures

+ One physician/practice attends both biannual meetings and claims CME credits

**PAYMENT**

Retrospective care (abstraction)

Prospective payment (3%)
<table>
<thead>
<tr>
<th>MOQC VBR Measures</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operative report with documentation of residual disease within 48 hours of cytoreduction for women with invasive ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>70%</td>
</tr>
<tr>
<td>Platin or taxane administered within 28 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>28 day mean</td>
</tr>
</tbody>
</table>
Generate Trusted Data
Shitanshu Uppal, MD
A New Era

QOPI database no longer available after December 2021
• Still available for QOPI-certified practices

Database **Task Force** is identifying new data engine

Opportunities

• EHR integration
• Increase numbers of cases
• New measures
Request for proposals (RFP) sent to candidate vendors

March 1, 2021
6-week turnaround

Proposals received & reviewed

Vendor presentations to task force

Vendor selection using scoring system

April 11

All are welcome

April 16, 1 – 5 pm (half of the vendors)
April 23, 1 – 5 pm (half of the vendors)
Virtual meetings

Data entry begins November 2021
## Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>VBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco cessation counseling administered or patient referred in past year</td>
<td></td>
</tr>
<tr>
<td>NK1RA &amp; olanzapine prescribed or administered with high emetic risk chemotherapy</td>
<td></td>
</tr>
<tr>
<td>NK1RA or olanzapine administered with first cycle low/moderate emetic risk (lower is better)</td>
<td></td>
</tr>
<tr>
<td>Complete family history documented in patients with invasive cancer</td>
<td></td>
</tr>
<tr>
<td>G-CSF administered to patients who received chemotherapy with non-curative intent (lower is better)</td>
<td></td>
</tr>
<tr>
<td>Hospice enrollment</td>
<td></td>
</tr>
<tr>
<td>Hospice enrollment &amp; enrollment within 7 days of death (lower is better)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy administered within the last 2 weeks of life (lower is better)</td>
<td></td>
</tr>
<tr>
<td>Operative report with documentation of residual disease within 48 hours of cytoreduction for women with invasive ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>X</td>
</tr>
<tr>
<td>Platin or taxane administered within 28 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>X</td>
</tr>
</tbody>
</table>
Break
Improving the Family History in People with Cancer MiGHT Project
Shayna Weiner, MPH
MiGHT: Michigan Genetic Hereditary Testing

Objectives
MiGHT Physician Survey

• Thanks to all who completed the MiGHT survey
• Please complete survey if you haven’t already
  • Paper or electronically

• CME Webinar on practical updates on genetic testing
  • Fee waived for all MOQC members
  • Access on MOCQ website & link will be shared in follow-up email
Not enough time to take a complete family history
Patients don’t know their family history
Guidelines change too often
No place to refer patients for counseling
Competing demands on time & attention

Barriers to completing a complete family history
MiGHT Project Overview

Goals
• Collection & documentation of a complete family history for all patients
• Referral of appropriate patients to genetic counseling & testing

Outcome
• Complete family history in the EMR

How we will get there
• Electronic family health history survey collection tool (FHHS)
• Hereditary cancer educational webinar (CME program, fee waived for MOQC members)
• Additional information support and resources for clinicians & patients

You can save lives.
Family Health History Survey

- Web-based
- Easy to use
- Adaptive based on responses
- Patient completes before seeing clinician
- Clinician receives a pedigree, PREMM5 Score, information
Project Team

Michigan Oncology Quality Consortium (MOQC)

• Jennifer Griggs MD, MPH—Principal Investigator
• Shitanshu Uppal MD—Co-Investigator
• Shayna Weiner, MPH
• Vanessa Aron

U-M Genetics

• Elena Stoffel MD, MPH—Principal Investigator
• Wendy Uhlmann, CGC—Co-Investigator
• Andrea Murad, CGC
• Sarah Austin, CGC
• Marie Louise Henry, CGC
• Colby Chase, CGC
• Erika Kopepe, MPH
• Erika Amini

Center for Health Communications Research (CHCR)

• Ken Resnicow, PhD—Principal Investigator
• Sarah Hawley, PhD—Co-I
• Elizabeth Hershey
• Stefanie Goodell
• Emerson Delacroix
• Matthew Demerath

University of Michigan School of Public Health

• Kelley Kidwell, PhD—Co-Investigator
• Scott Roberts, PhD—Co-Investigator

Michigan Department of Health and Human Services (MDHHS) Public Health Genomics

• Dominic Smith, MSA
• Maricar Macalincag
Advisory Board

Broad representation by key stakeholders with diverse experience
Patients, oncologists, nurses, genetic counselors, practice administrators

Current Members

Kevin Myers  Cynthia Koch
Daniel Dry Dock Shockley  Kathy LaRaia
Monica Dottei  Laura Johnson
Bob Whalen  Nanci Petruccelli
Tina Roberts  Adriane Lombardo
Laura Wangler  Dana Zakalik
Mary Mobley  Jo Ann Hirth
Morgan Hnatiuk  Helen Burns
Resources

• CME Webinar
  • Free for MOQC providers
  • https://ww2.highmarksce.com/micme/activity/202005280EM

• Michigan’s Hereditary Cancer Hotline
  • 1-866-852-1247

• MDHHS Website – Provider Resources
  • Hereditary Cancer Toolkit
  • https://www.michigan.gov/mdhhs/0,5885,7-339-73971_4911_4916_47257_68337_94208_94213---,00.html

• Genetic Counselor finder
  • https://migrc.org/providers/michigan-cancer-genetics-alliance/mcga-directory-of-cancer-genetic-services-providers/
Questions?

• Contact Information
  • Shayna Weiner - Project Coordinator
    • shaynaw@med.umich.edu or sweiner@moqc.org
    • 734-615-1807
  • MiGHT team
    • might@moqc.org
Measure Selection Strategy

- Means something
- Feasible to measure
- Addresses variations in care
- Evidence-based
- Addresses gap in care
- Aligns with MIPS/NQF
- Sufficient numbers
- Is part of the value equation
Partnership with Michigan Surgical Quality Collaborative (MSQC)
  - Surgical Outcomes

New Database
  - Patient Reported Outcomes

Standardization of Care
  - Imaging

End of life care
Questions
Closing Items

• MOQC Medical Oncology Biannual Meeting – **Virtual**
  
  June 2021 [https://moqc.org/events/](https://moqc.org/events/)
  
  Friday, June 18, 2021, 9 AM - 1 PM
  
  Register now at [www.moqc.org](http://www.moqc.org)
  
• MOQC Gynecologic Oncology Fall Biannual Meeting – **TBD**
  
  October 2021 [https://moqc.org/events/](https://moqc.org/events/)
  
  Saturday, October 9, 2021
  
  Register now at [www.moqc.org](http://www.moqc.org)
  
• Claim your CME/CEU credit for this meeting
<table>
<thead>
<tr>
<th>Abstraction</th>
<th>CLINICAL</th>
<th>GRANT-FUNDED</th>
<th>GYNECOLOGIC ONCOLOGY</th>
<th>INTERDISCIPLINARY PARTNERSHIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Round 1 Abstraction</td>
<td>Chemotherapy-Induced Nausea and Vomiting (CINV) - Antiemetics</td>
<td>Patient-Reported Outcomes in Oncology (PROMOnc)</td>
<td>Gyn Onc Educational Series</td>
<td>Hospice</td>
</tr>
<tr>
<td></td>
<td>Oral Oncolytics</td>
<td></td>
<td>Ovarian Cancer Resources</td>
<td>Palliative Radiation Therapy Pathway</td>
</tr>
<tr>
<td></td>
<td>Tobacco Cessation Program</td>
<td></td>
<td>Past Meeting Library</td>
<td>Pharmacists Optimizing Oncology Care Excellence in Michigan (POEM)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standardized Op Note</td>
<td>Primary Care Oncology Model (PCOM)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VTE Khorana Calculator</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VTE Prophylaxis Calculator</td>
<td></td>
</tr>
</tbody>
</table>
Resources

GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series
Ovarian Cancer Resources
Past Meeting Library
Standardized Op Note
VTE Khorana Calculator
VTE Prophylaxis Calculator

https://moqc.org

Gynecologic Oncology Educational Series

Support GYOEDU.org
Become a patron

Who are we?

GYOEDU was founded in 2020. We aim to build an inclusive educational community for GYN Oncology based on a model of high-quality, easily-accessible, peer-reviewed content free from commercial bias. We focus on goals and objectives for GYN Oncology fellows and those interested in pursuing fellowship. Our shared vision is knowing that strength comes from ensuring the success of those around us. Just as the highest quality health care organizations implement reliable and reproducible systems in order to elevate patient care, we aim to provide standardized curricula for teaching GYN Oncology throughout the world.

GYOEDU Team
Standardized Operative Note

Checklist for Ovarian Cancer Operative Note Dictation

Please make sure to include the following data elements in your operative note.

- **Debulking Status** – Primary vs. Interval Debulking
- **Staging Information** – If available based on imaging (for example, at least stage IIIc for a patient with a biopsy-proven lesion of the omentum) [Link to ovarian cancer staging]
- **Surgery Type** – Open/Robotic/Laparoscopic
- **Residual Disease Status** – Please specify if:
  - No residual disease (R0 or no visible disease)
  - Optimally debulked (1-5 mm largest visible disease)
  - Optimally debulked (6-10 mm visible disease)
  - Sub-optimally debulked (>10 mm disease residual)
    - For suboptimally debulked patients, specify the size and location of residual disease
- **Surgical Complexity Scoring** – Use the calculator below to get the score
  
Resources

https://moqc.org

Additional flyers:

- Ovarian Cancer Resources
- Ovarian Cancer Staging
- Ovarian Cancer Testing
- Ovarian Cancer Treatments
- Ovarian Cancer Treatment Team
- Types of Ovarian Cancer

Order MOQC Ovarian Cancer Printed Materials
Please make sure to include the following data elements in your operative note.

- **Debulking Status** – Primary vs. Interval Debulking
- **Staging Information** – If available based on imaging (for example, at least stage IIIc for a patient with a biopsy-proven lesion of the omentum) [Link to ovarian cancer staging](https://moqc.org)
- **Surgery Type** – Open/Robotic/Laparoscopic
- **Residual Disease Status** – Please specify if:
  - No residual disease (R0 or no visible disease)
  - Optimally debulked (1-5 mm largest visible disease)
  - Optimally debulked (6-10 mm visible disease)
  - Sub-optimally debulked (>10 mm disease residual)
    - For suboptimally debulked patients, specify the size and location of residual disease
- **Surgical Complexity Scoring** – Use the calculator below to get the score
Khorana Risk Score for Venous Thromboembolism in Cancer Patients

Predicts risk of VTE for cancer patients depending on type of cancer and other factors.

**INSTRUCTIONS**
Use in general cancer patients (i.e., solid tumors and lymphomas). Do not use in patients with brain tumors or myelomas.

**When to Use**
- When to Use
- Pearls/Pitfalls
- Why Use

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>+2</td>
</tr>
<tr>
<td>Pancreas</td>
<td>+2</td>
</tr>
<tr>
<td>Lung</td>
<td>+1</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>+1</td>
</tr>
</tbody>
</table>

**Result:**

**About the Creator**
Dr. Alok Khorana

**Also from MDCalc...**
- POMPE-C Tool
- Hestia Criteria
- PERC Rule

**MOQC VTE Calculator**

Age:
- ≤40
- 41-60
- 61-74
- ≥75

Type of Surgery:
- Minimally Invasive
- Open
- Vaginal/Vulvar

Operation Time:
- ≤45 mins
- 45 to 180 mins
- >180 mins

**Possible Values**
- No 0
- Yes +1
- Yes +2

**Possible Values**
- No 0
- Yes +1
- Yes +1
- Yes +1
- Yes +1
- Yes +1

**Resources**
https://moqc.org

**Gynecologic Oncology**
- Gyn Onc Educational Series
- Ovarian Cancer Resources
- Past Meeting Library
- Standardized Op Note
  - VTE Khorana Calculator
  - VTE Prophylaxis Calculator
Two Continuing Education Webinars

Genetic Risk Assessment for Hereditary Cancer Syndromes

- **Release Date:** Fri, 1/15/21
- **Termination Date:** Fri, 12/31/21
- **Credits available:**
  - **AMA PRA Category 1:** 0.75
  - **Participation:** 0.75

Fee Waved for MOQC Members

In Partnership with the Michigan Department of Health and Human Services

Survivorship Programs to Support Quality of Life

- **Release Date:** Tues, 3/30/21
- **Termination Date:** Pending
- **Credits available:**
  - **AMA PRA Category 1:** Approval Pending
  - **Participation:** Approval Pending

Fee Waved for MOQC Members

https://moqc.org/resources/continuing-education-opportunities/
Continuing Education Credit – Creating an Account

Steps to create a MiCME Account:
1. Go to https://ww2.highmarksce.com/micme/
2. Click the “Create a MiCME Account” tile at the bottom of the screen
3. Under New User? click “Create a MiCME Account”
4. Enter the Profile Information questions, confirm consent, and click “Create a MiCME Account”
5. Enter your password and complete your profile. Your MiCME account is created and you can now claim continuing education credits

Steps to Claim Credits and Print a Transcript
1. Once your MiCME account has been created, navigate to your Dashboard
2. Click on Claim Credits and View Certificates
3. Locate ‘MOQC Spring 2020 Regional Meeting’ in the Activities Available for Credit Claiming section
4. Under Action, click on Claim. Add Credit.
5. Enter the number of credits you are claiming and the “I Attest” button.
6. Complete the evaluation.
7. Click the Submit button
8. Scroll down to the Awarded Credits section to view or print your certificate and/or comprehensive University of Michigan CME transcript.

If you have any difficulties, email varon@moqc.org
We will assist you and resolve any issue!
Thank You!